Research and development

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced scientific research and produces modern drugs. The company also conducts effective marketing of its own products. Our drugs help thousands of patients to live better and longer lives.

Meet our pipeline

Innowacyjne leki

Meet our pipelineWe create
innovative drugs, that will change
the lives of patients globally

Co-financed projects

  • CBITE
    Preclinical and clinical development of a first-in-class, innovative, bispecific immunotherapeutic agent as a drug candidate in cancer immunotherapy 
  • CITY
    Development of an innovative, class-leading, low-molecular, double-oriented therapeutic agent having immunomodulating and cytotoxic effects as a drug candidate for theRead more »
  • BAAP
    Development of an innovative platform for the production of bispecific constructions based on Phage Display technique and the preclinical andRead more »
  • KICHAI
    Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases
  • TrackB
    TrackB - Preclinical and clinical development of innovative TrkB antagonist in treatment of nervous system disorders.
  • UBA
    UBA – Preclinical and clinical development of the ubiquitin-proteasome system inhibitor as an innovative drug used in cancer treatment.
  • AMDBP
    AMDBP – Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinicalRead more »
  • GATE
    GATE – Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment
  • FAIND
    FAIND – A new diabetes treatment using an innovative FGF1 protein analogue.
  • DISK
    A new form of S-ketamine in treatment of depression
  • PIKCel
    PIKCel – developing inhalation technology in asthma and COPD treatment
  • NoteSzHD
      NoteSzHD – "New therapy in psychotic disorders and Huntington's disease with special focus on cognitive deficits" .
  • NATco
      NATco – "New anti-amyloid therapy for cognitive disorders"
  • CELONKO
      CELONKO – "Development of modern biomarkers and development of an innovative FGFR kinases inhibitor"
  • JAKSON
    JAKSON – Selective JAK/ROCK kinases inihibitor in treatment of immune-mediated diseases
  • RDC
    “Fostering Celon Pharma S.A. research infrastructure by creating a Research&Development Centre (RDC)”

Our Research and Development Center

Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.

One huge advantage of Celon Pharma S.A. is its strong research and development facilities which allow us to create whole new classes of effective drugs. The research and development department in Celon Pharma S.A.employs over 160 scientists, of which one in four have PhD titles in molecular biology, pharmacy or chemistry.

We invest in the development of innovative pharmaceutical products which have the potential to treat cancers, neurological diseases, diabetes and other metabolic disorders. We have obtained financial resources for research into new drugs from the sale of generic drugs, as well as from the EU funds obtained under the Innovative
Economy programme.

Publications

See ours
publications and articles